ODS-101

N/A

Report date: 2025/06/30 20:00:06
NME

Base Information

Drug NameODS-101
Drug Alias NameODS-101ODS 101OPM-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase RIPK2 inhibitors
TargetsSerine/threonine-protein kinase RIPK2
Therapy Area/IndicationsCystitis, InterstitialInflammatory Bowel DiseasesColitis, Ulcerative +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncodesign Biotechnology SA
China Registration ClassN/A

Develop Information

Active CompaniesOncodesign Precision MedicineOncodesign Biotechnology SA
Inactive CompaniesN/A
Active IndicationsCystitis, InterstitialInflammatory Bowel DiseasesColitis, Ulcerative +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A